SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs Q3 earnings beat expectations and came with raised full-year and Q4 guidance, with strong U.S. commercial AI growth drawing attention. Bulls celebrated the results, while skeptics argued that a premium valuation and weakness across AI stocks could still pressure shares, contributing to a volatile reaction.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apples fiscal Q4 earnings report, its first under new CEO John Ternus, is driving attention, with traders focused on holiday-quarter guidance, iPhone demand and rising memory costs effect on margins. Some hope a strong report could steady a battered tech market, while others see high expectations and valuation as leaving room for a selloff.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

A tech- and AI-linked selloff is driving concern about the broader market, with traders debating whether worries over AI spending and valuations signal a deeper correction or a buying opportunity. Midterm-election uncertainty and upcoming Apple and Palantir results are adding to volatility, while bulls look for a rebound and bears expect further downside.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs upcoming earnings and guidance dominate discussion as the stock has sold off sharply with semiconductor shares after Intels weak report. Traders are split on whether strong results could spark a rebound or whether valuation concerns and a cautious outlook would extend the decline.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is drawing attention amid a sharp Nasdaq and technology selloff, with traders focused on whether heavy AI spending can generate adequate returns or whether the AI trade is unwinding. Bearish calls and concern about further losses compete with dip-buying and expectations of a technical bounce; midterm uncertainty is adding to volatility.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvells all-stock agreement to acquire Lumentum has sparked a sharp selloff, with traders focused on shareholder dilution, the long wait for closing, and whether the deals price and execution risks are justified. Some see the combination as a strategic bet on optical connectivity for AI data centers, while others argue the deal undermines value for existing shareholders amid a broader tech selloff.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs REGAL Phase 3 trial reached its prespecified 80th death event, triggering final analysis and anticipation of GPS topline results; the milestone was followed by a sharp selloff. Traders disagree over whether the decline reflects profit-taking and binary-trial risk or suspected manipulation or an information leak, with no results yet establishing the trials outcome.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is drawing attention amid a sharp semiconductor and tech selloff, with traders debating whether concerns about AI spending and a broader risk-off move point to a deeper correction; claims of forced liquidations remain speculation. Dip buyers are looking for a rebound, while bears warn that the funds 3x leverage can magnify losses and decay.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Marvells agreed all-stock acquisition of Lumentum has triggered a sharp selloff, as Lumentum holders focus on the fixed share exchange, exposure to Marvells falling stock and the long path to closing. Traders debate whether the deals dilution and timing make it unfavorable for shareholders or whether the strategic fit in AI optical connectivity supports the combination over the longer term.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

A sharp semiconductor-sector pullback, amid worries that heavy AI infrastructure spending may not deliver returns quickly enough and weak guidance from major chipmakers, is driving attention to SOXX. Traders are split between calling the decline an AI-bubble unwind with more downside ahead and treating it as an oversold correction and buying opportunity, with many watching key technical support levels.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MRNA On Track To Be September's No. 2 S&P 500 Stock — But These 5 Smaller Health Care Names Did Even Better

Equity

Five smaller stocks with market caps above $100 million beat MRNA’s monthly gain: INDP rose 249%, CYPH 124%, MNOV 85%, GRAL 58% and SRZN 53%.

MediciNova (MNOV) Reports Q2 Loss, Tops Revenue Estimates

MediciNova (MNOV) delivered earnings and revenue surprises of +16.67% and +205.63%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

MaxCyte, Inc. (MXCT) Reports Q2 Loss, Beats Revenue Estimates

MaxCyte (MXCT) delivered earnings and revenue surprises of +33.33% and +11.86%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates

Alector (ALEC) delivered earnings and revenue surprises of +12.50% and +283.37%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

MediciNova (MNOV) Expected to Announce Quarterly Earnings on Wednesday

MediciNova (NASDAQ:MNOV) will be releasing earnings after the market closes on Wednesday, May 13. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-13-medicinova-inc-stock...

D. Boral Capital Reiterates Buy Rating for MediciNova (NASDAQ:MNOV)

D. Boral Capital restated a "buy" rating and issued a $9.00 price target on shares of MediciNova in a report on Monday...

MediciNova, Inc. (NASDAQ:MNOV) Sees Large Decrease in Short Interest

MediciNova, Inc. (NASDAQ:MNOV - Get Free Report) saw a large decline in short interest in April. As of April 15th, there was short interest totaling 168,023 shares, a decline of 16.4% from the March...

MediciNova, Inc. (NASDAQ:MNOV) Receives Consensus Rating of "Moderate Buy" from Brokerages

Shares of MediciNova, Inc. (NASDAQ:MNOV - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seven ratings firms that are currently covering the firm...

MediciNova (NASDAQ:MNOV) Share Price Crosses Above Two Hundred Day Moving Average   - Here's Why

MediciNova (NASDAQ:MNOV) Shares Pass Above 200 Day Moving Average - Should You Sell...

MediciNova (NASDAQ:MNOV) Shares Cross Above 200 Day Moving Average - Here's What Happened

MediciNova (NASDAQ:MNOV) Stock Crosses Above 200-Day Moving Average - Should You Sell...

MediciNova, Inc. is a biopharmaceutical company, which focuses on developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus. Its programs include MN-001, MN-166 neurology diseases, and MN-221 respiratory diseases. The company was founded by Yuichi Iwaki on September 26, 2000 and is headquartered in La Jolla, CA.

Medicinova Inc

Neutral Sentiment

<ul class="summary-bullets"><li>INDP’s rally followed a $24 million share sale, with proceeds potentially supporting early research into a sleep-related device.</li><li>Former biotech CYPH gained as its Zcash mining operation added 3,023 ZEC to its treasury.</li><li>MNOV completed patient visits in the blinded portion of its ALS trial, while a favorable FDA advisory panel vote lifted attention on GRAL’s Galleri test.</li></ul>Moderna, Inc. (MRNA) is on track to become September’s second-best performer in the S&amp;P 500, but five smaller stocks have delivered even larger gains this month, driven by developments ranging from an impending ALS trial readout to a cancer-test regulatory review, and, in one case, a Zcash strategy.<a href="https://stocktwits.com/symbol/MRNA">Moderna (MRNA)</a> is up about 39% so far this month. Among stocks with market caps above $100 million,&nbsp;<a href="https://stocktwits.com/symbol/INDP">Indaptus Therapeutics (INDP)</a> has surged about 249%, followed by&nbsp;<a href="https://stocktwits.com/symbol/CYPH">Cypherpunk Technologies (CYPH)</a> at 124%,&nbsp;<a href="https://stocktwits.com/symbol/MNOV">MediciNova (MNOV)</a> at 85%,&nbsp;<a href="https://stocktwits.com/symbol/GRAL">GRAIL (GRAL)</a> at 58% and&nbsp;<a href="https://stocktwits.com/symbol/SRZN">Surrozen (SRZN)</a> at 53%.&nbsp;<img src="https://news.stocktwits-cdn.com/mrna_rally_c347f1f47e.png" alt="mrna rally.png"><h2 class="st-heading-2">Moderna’s Phase 3 Win Faces Its Next Test&nbsp;</h2>The foundation for Moderna’s rally was laid in August, when the company and partner Merck announced that their Phase 3 trial of personalized cancer vaccine Intismeran autogene plus Keytruda met its primary endpoint in patients whose melanoma had been surgically removed. The companies also reported success on a key secondary endpoint, but have not yet presented the detailed trial results.This week, Moderna gave investors a date for that closer examination: the Phase 3 findings will be presented at a Presidential Symposium on Oct.24 during the European Society for Medical Oncology congress.&nbsp;At a recent Bernstein healthcare conference, CEO Stéphane Bancel said, “Moderna has been, since day one, an mRNA platform company,” calling intismeran “only our first oncology product.” Moderna and Merck have nine studies ongoing, he said, but they still must test the potential for the treatment to work in other cancers. Chief development officer David Berman said he was “very confident that we have a strong case for approval” in melanoma.&nbsp;Stocktwits sentiment for MRNA was ‘extremely bullish’ a month ago, slipped to ‘bearish’ a week ago and recovered to ‘bullish’ on Thursday before returning to ‘extremely bullish’ in the latest reading. Over the month, message volume rose 336% and the ticker’s watcher base grew 5%.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/mrna_ss_b81951629d.png" alt="mrna ss.png" width="645" height="355"><figcaption>MRNA sentiment and message volume as of September 24 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">INDP Surges On $24M Financing&nbsp;</h2>Indaptus Therapeutics has delivered the largest September gain of the group as investors assess a possible new direction for the company. Last month, Indaptus said it had stopped enrolling patients in its Decoy20 cancer study and had no active clinical development programs. However, earlier this month the company announced a financing deal and disclosed plans to explore a neurotechnology device for certain sleep-related conditions, with a potential future FDA submission in view.&nbsp;The firm also agreed to sell 20.3 million shares at $1.18 each in a private placement expected to raise about $24 million. The price was about 1% above the deal’s Nasdaq pricing benchmark, though about 3% below INDP’s close before the agreement.&nbsp;Stocktwits sentiment for INDP shifted from ‘bullish’ a month ago to ‘bearish’ a week ago and remained ‘bearish’ in the latest reading. The ticker’s watcher base edged up 0.3% over the month.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/indp_ss_9ade02b797.png" alt="indp ss.png" width="640" height="344"><figcaption>INDP sentiment and message volume as of September 24 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">CYPH Rallies As Zcash Mining Adds To Treasury&nbsp;</h2>Cypherpunk Technologies, previously known as Leap Therapeutics, changed its name and ticker last year to reflect a Zcash-based strategy. Its remaining cancer-drug operations sit within a Leap Therapeutics unit.&nbsp;Cypherpunk announced this week the launch of a 4.2 GSol/s Zcash mining fleet and said the operation had generated 3,023.13 ZEC in its first weeks, with the coins added to its treasury. The company had previously reported holdings of 323,394.38 ZEC as of Aug. 11.&nbsp;Stocktwits sentiment for CYPH remained ‘extremely bullish’ throughout the past month, though its score eased from (91/100) to (79/100). Over the same period, message volume surged 5,200%, and the ticker’s watcher base grew 4%.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/cyph_ss_d24fe58448.png" alt="cyph ss.png" width="629" height="343"><figcaption>CYPH sentiment and message volume as of September 24 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">MNOV Gains Ahead Of Year-End ALS Results&nbsp;</h2>MediciNova has climbed as investors look ahead to results from its Phase 2b/3 Combat-ALS trial of MN-166, or ibudilast. On Thursday, the company said the final patient had completed the last visit in the trial’s blinded portion. The study randomized 234 participants, and MediciNova expects to report topline findings by year-end. Its primary endpoint combines measures of function and survival. CEO Yuichi Iwaki said the company’s focus had shifted to “database lock and rigorous analysis of the study data.”&nbsp;Stocktwits sentiment for MNOV rose from ‘bullish’ a month ago to ‘extremely bullish’ a week ago, but has since fallen back through ‘bullish’ to ‘bearish’ in the latest reading. The ticker’s watcher base grew 0.6% over the month.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/mnov_ss_84eff47815.png" alt="mnov ss.png" width="646" height="353"><figcaption>MNOV sentiment and message volume as of September 24 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">GRAIL’s Galleri Wins A Favorable Panel Vote&nbsp;</h2>GRAIL’s September catalyst was a recent FDA advisory committee meeting on Galleri, its blood test intended to detect signals associated with multiple cancers in adults aged 50 and older. The panel&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/gral-s-galleri-cancer-test-clears-fda-panel-safety-vote-splits-on-effectiveness/cZM4avyRBBh">voted</a> 10-0 in support of the test’s safety, 6-4 on effectiveness, and 7-2, with one abstention, that its benefits outweighed its risks. Galleri is intended to be used alongside existing recommended cancer screenings, not as a replacement.&nbsp;The favorable votes advanced GRAIL’s case, but the FDA has yet to decide whether to approve the test and is not bound by the panel’s recommendation.Stocktwits sentiment for GRAIL shifted from ‘bullish’ a month ago to ‘bearish’ a week ago, then surged to ‘extremely bullish’ in the latest reading. The ticker’s watcher base grew 1% over the month.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/grail_ss_65154b4dbf.png" alt="grail ss.png" width="651" height="351"><figcaption>GRAL sentiment and message volume as of September 24 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">SRZN’s Eye-Drug Filing Sets Up Clinical Trial&nbsp;</h2>Surrozen submitted an investigational new drug application earlier this month for SZN-8141, an experimental antibody for diabetic macular edema. The treatment will combine activation of the Wnt pathway with inhibition of VEGF, a target already used in retinal-disease treatments. The company aims to begin an early-stage study by year-end, subject to regulatory clearance, and expects initial data in the second half of 2027.&nbsp;Stocktwits sentiment for SRZN moved from ‘neutral’ a month ago to ‘bullish’ a week ago, dipped to ‘bearish’ on Thursday, then rebounded to ‘extremely bullish’ in the latest reading. Over the month, message volume rose 50%, and the ticker’s watcher base edged up 0.1%.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/srzn_ss_4bd078b953.png" alt="srzn ss.png" width="633" height="348"><figcaption>SRZN sentiment and message volume as of September 24 | Source: Stocktwits</figcaption></figure>Year to date, MRNA has surged about 561%, followed by CYPH at 252%, MNOV at 102%, SRZN at 49%, GRAL at 46% and INDP at 37%.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/bb-stock-qnx-royalties-star-of-the-show-president-holdings-revealed/cZMarhGRBad">BB Stock Eyes Best Week In 3 Months As QNX Royalties Become ‘Star Of The Show’ — President’s Holdings Revealed&nbsp;</a>

In this photo illustration, the American pharmaceutical and biotechnology company Moderna logo is displayed on a smartphone screen. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)

Cypherpunk Technologies Inc.

GRAIL Inc.

iShares Biotechnology ETF

Indaptus Therapeutics Inc

Moderna Inc

Surrozen Inc

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

Up more than 3%

Flat to up 3%

Flat to down 3%

Down more than 3%

What’s your expected total return for the S&amp;P 500 ($SPY) in November?

Stocktwits

What’s your expected total return for the S&P 500 (

Current Price	$1.44
Prev Close	$1.40
Open	$1.40
Dividend Yield	0.00%
50-Day Moving Average	$1.79
Beta	0.53
Avg. Volume	866,551.98
PE Ratio	-6.40

52-Week High	$3.90
52-Week Low	$1.22
Market Capitalization	$68.91M
EPS (Annual)	-$0.2445
Price to Book	1.85
Revenue Per Employee	$68,276.17

Feed

News

Sentiment

Earnings

Fundamentals

Info

MNOV Fundamentals